Q-omics provides the consensus-scored TRAJ20 profile across patient tissues and cancer cell-line models. TRAJ20 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRAJ20 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, TRAJ20 RNA expression shows 12,598 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where TRAJ20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ20 survival associations across molecular data types. TRAJ20 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ20 RNA expression–survival associations across cancer types. High TRAJ20 expression shows unfavorable associations in KIRP, UCEC, PCPG, GBM, BRCA and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TRAJ20 RNA expression.
This table summarizes TRAJ20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ20 shows higher tumor expression in KIRC. The KIRC box plot shows higher TRAJ20 RNA expression in tumor versus normal tissue (log2 FC = +0.160, t-test p = .019).
This table shows molecular features associated with TRAJ20 in patient tissues and cancer cell lines. In patient samples, TRAJ20 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
